BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10495852)

  • 1. [Development and establishment of a yeast-based stop codon assay for detection of NF2 gene premature-terminating mutations].
    Kobayashi H
    Hokkaido Igaku Zasshi; 1999 Sep; 74(5):377-86. PubMed ID: 10495852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.
    Koga H; Araki N; Takeshima H; Nishi T; Hirota T; Kimura Y; Nakao M; Saya H
    Oncogene; 1998 Aug; 17(7):801-10. PubMed ID: 9779996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurofibromatosis type 2 (NF2)].
    Araki N; Takeshima H; Saya H
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of a detection system (APC yeast color assay) of APC mutations by color change of yeast].
    Furuuchi K
    Hokkaido Igaku Zasshi; 2000 Nov; 75(6):385-97. PubMed ID: 11193931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detectability and diagnostic criteria of p53 gene mutations in human oral squamous cell carcinoma using yeast functional assay].
    Kashiwazaki H
    Hokkaido Igaku Zasshi; 1997 Mar; 72(2):211-24. PubMed ID: 9145313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for large mutations of the NF2 gene.
    Kluwe L; Nygren AO; Errami A; Heinrich B; Matthies C; Tatagiba M; Mautner V
    Genes Chromosomes Cancer; 2005 Apr; 42(4):384-91. PubMed ID: 15645494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of the NF2 gene in sporadic meningiomas by denaturing high-performance liquid chromatography.
    Kim JH; Kim IS; Kwon SY; Jang BC; Suh SI; Shin DH; Jeon CH; Son EI; Kim SP
    Int J Mol Med; 2006 Jul; 18(1):27-32. PubMed ID: 16786152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of heterozygous nonsense mutations in genes of interest using an Escherichia coli-based stop codon assay.
    Moon YJ; Kang Y; Choi JH; Lee KH
    Biotechnol Appl Biochem; 2007 Feb; 46(Pt 2):137-43. PubMed ID: 16995837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
    Kley N; Seizinger BR
    Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene.
    Baser ME;
    Hum Mutat; 2006 Apr; 27(4):297-306. PubMed ID: 16521120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of novel NF2 mutations by an RNA mismatch cleavage method.
    Faudoa R; Xue Z; Lee F; Baser ME; Hung G
    Hum Mutat; 2000; 15(5):474-8. PubMed ID: 10790209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases.
    Ferrer M; Schulze A; Gonzalez S; Ferreiro V; Ciavarelli P; Otero J; Giliberto F; Basso A; Szijan I
    Neurosci Lett; 2010 Aug; 480(1):49-54. PubMed ID: 20553997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible localization of a neurofibromatosis type 2 modifier gene?
    Bruder CE; Ichimura K; Blennow E; Ikeuchi T; Yamaguchi T; Yuasa Y; Collins VP; Dumanski JP
    Genes Chromosomes Cancer; 1999 Jun; 25(2):184-90. PubMed ID: 10338003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further genotype--phenotype correlations in neurofibromatosis 2.
    Selvanathan SK; Shenton A; Ferner R; Wallace AJ; Huson SM; Ramsden RT; Evans DG
    Clin Genet; 2010 Feb; 77(2):163-70. PubMed ID: 19968670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques.
    Andreutti-Zaugg C; Scott RJ; Iggo R
    Cancer Res; 1997 Aug; 57(15):3288-93. PubMed ID: 9242462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
    Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
    Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A point mutation associated with a severe phenotype of neurofibromatosis 2.
    MacCollin M; Braverman N; Viskochil D; Ruttledge M; Davis K; Ojemann R; Gusella J; Parry DM
    Ann Neurol; 1996 Sep; 40(3):440-5. PubMed ID: 8797533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF2: the wizardry of merlin.
    Xiao GH; Chernoff J; Testa JR
    Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and distribution of NF2 mutations in schwannomas.
    Jacoby LB; MacCollin M; Barone R; Ramesh V; Gusella JF
    Genes Chromosomes Cancer; 1996 Sep; 17(1):45-55. PubMed ID: 8889506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.